---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-014445"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2025-06-10T23:59:59+00:00"
generated_at: "2026-05-19T16:04:17.808228+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma CEO Kraig Higginson Steps Down, Michael C. Howe Appointed as New CEO

## Summary
- Kraig Higginson resigned as CEO effective June 10, 2025, and will serve as Executive Chairman.
- Board appointed Michael C. Howe, previously an independent board member, as CEO effective June 10, 2025.
- Howe led MinuteClinic from 19 clinics to sale to CVS in 2006, delivering nearly sixfold return for investors.
- Howe has 40+ years experience at Procter & Gamble, PepsiCo, Arby's (CEO), and early-stage healthcare companies.
- Press release issued June 10, 2025, detailing leadership transition and Howe's background.

## SEC filing metadata
- accession: 0001641172-25-014445
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2025-06-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000164117225014445/0001641172-25-014445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000164117225014445/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-014445
- JSON: https://secwatch.observer/filing/0001641172-25-014445.json
- Plain text: https://secwatch.observer/filing/0001641172-25-014445.txt

## Key facts
- Executive change
  Michael Howe was appointed as Chief Executive Officer at Aspire Biopharma Holdings, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board of Directors appointed Michael Howe, currently a member of the Board of Directors, to serve as Chief Executive Officer of the Company, effective June 10, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000164117225014445/0001641172-25-014445-index.htm
- Executive change
  Kraig Higginson resigned as Chief Executive Officer at Aspire Biopharma Holdings, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On June 10, 2025, Kraig Higginson, Chief Executive Officer of Aspire Biopharma Holdings, Inc. (the “Company”), notified the Board of Directors of his intention to step down from the role of Chief Executive Officer, effective June 10, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000164117225014445/0001641172-25-014445-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.